269 related articles for article (PubMed ID: 21332865)
1. Indications and outcome of implantable cardioverter-defibrillators for primary and secondary prophylaxis in patients with noncompaction cardiomyopathy.
Caliskan K; Szili-Torok T; Theuns DA; Kardos A; Geleijnse ML; Balk AH; van Domburg RT; Jordaens L; Simoons ML
J Cardiovasc Electrophysiol; 2011 Aug; 22(8):898-904. PubMed ID: 21332865
[TBL] [Abstract][Full Text] [Related]
2. Implantable cardioverter-defibrillators in patients with left ventricular noncompaction.
Kobza R; Jenni R; Erne P; Oechslin E; Duru F
Pacing Clin Electrophysiol; 2008 Apr; 31(4):461-7. PubMed ID: 18373765
[TBL] [Abstract][Full Text] [Related]
3. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
Marín F; Gimeno JR; Payá E; García-Alberola A; Pérez-Alvarez L; Fernández X; de la Morena G; Sogorb F; Castro-Beiras A; Valdés M; Martínez JG; Monserrat L
Rev Esp Cardiol; 2006 Jun; 59(6):537-44. PubMed ID: 16790196
[TBL] [Abstract][Full Text] [Related]
4. Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy -- dilemmas and difficulties.
Przybylski A; Małecka L; Pytkowski M; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Ruzyłło W; Szwed H
Kardiol Pol; 2005 Oct; 63(4):391-7; discussion 398. PubMed ID: 16273479
[TBL] [Abstract][Full Text] [Related]
5. The ICD for primary prevention in patients with inherited cardiac diseases: indications, use, and outcome: a comparison with secondary prevention.
Olde Nordkamp LR; Wilde AA; Tijssen JG; Knops RE; van Dessel PF; de Groot JR
Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):91-100. PubMed ID: 23275262
[TBL] [Abstract][Full Text] [Related]
6. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.
Cuoco FA; Spencer WH; Fernandes VL; Nielsen CD; Nagueh S; Sturdivant JL; Leman RB; Wharton JM; Gold MR
J Am Coll Cardiol; 2008 Nov; 52(21):1718-23. PubMed ID: 19007692
[TBL] [Abstract][Full Text] [Related]
7. Rates and predictors of appropriate implantable cardioverter-defibrillator therapy delivery: results from the EVADEF cohort study.
Otmani A; Trinquart L; Marijon E; Lavergne T; Waintraub X; Lepillier A; Chatellier G; Le Heuzey JY;
Am Heart J; 2009 Aug; 158(2):230-237.e1. PubMed ID: 19619699
[TBL] [Abstract][Full Text] [Related]
8. Primary prevention of sudden cardiac death by implantable cardioverter-defibrillator therapy in Chinese patients with heart failure: a single-center experience.
Chen TB; Cheng KA; Gao P; Cheng ZW; Fan JB; Jiang XC; Fang Q
Chin Med J (Engl); 2010 Apr; 123(7):848-51. PubMed ID: 20497676
[TBL] [Abstract][Full Text] [Related]
9. Predictors of appropriate implantable cardioverter defibrillator (ICD) therapy in primary prevention patients with ischemic and nonischemic cardiomyopathy.
Verma A; Sarak B; Kaplan AJ; Oosthuizen R; Beardsall M; Wulffhart Z; Higenbottam J; Khaykin Y
Pacing Clin Electrophysiol; 2010 Mar; 33(3):320-9. PubMed ID: 19796352
[TBL] [Abstract][Full Text] [Related]
10. Left ventricular ejection fraction and absence of ACE inhibitor/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population.
Obeyesekere MN; Chan W; Stub D; Prabhu S; Teo EP; Toogood G; Mariani J; Broughton A; Kistler PM
Pacing Clin Electrophysiol; 2010 Jun; 33(6):696-704. PubMed ID: 20059719
[TBL] [Abstract][Full Text] [Related]
11. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
Syska P; Przybylski A; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Gepner K; Pytkowski M; Kowalik I; Maczyńska-Mazuruk R; Ruzyłło W; Szwed H
J Cardiovasc Electrophysiol; 2010 Aug; 21(8):883-9. PubMed ID: 20132378
[TBL] [Abstract][Full Text] [Related]
12. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention.
Bhonsale A; James CA; Tichnell C; Murray B; Gagarin D; Philips B; Dalal D; Tedford R; Russell SD; Abraham T; Tandri H; Judge DP; Calkins H
J Am Coll Cardiol; 2011 Sep; 58(14):1485-96. PubMed ID: 21939834
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of ventricular tachyarrhythmias occurring in ischemic versus nonischemic patients implanted with a biventricular cardioverter-defibrillator for primary or secondary prevention of sudden death.
Boriani G; Gasparini M; Lunati M; Santini M; Landolina M; Vincenti A; Curnis A; Bocchiardo M; Padeletti L; Biffi M; Allaria L; Denaro A;
Am Heart J; 2006 Sep; 152(3):527.e1-11. PubMed ID: 16923425
[TBL] [Abstract][Full Text] [Related]
14. A comparison of outcomes for patients receiving implantable cardioverter defibrillators for primary vs secondary-prevention.
Giedrimas A; Giedrimiene D; Guertin D; White CM; Clyne CA; Kluger J
Conn Med; 2008; 72(6):329-33. PubMed ID: 18610705
[TBL] [Abstract][Full Text] [Related]
15. The role of implantable cardioverter defibrillator for primary vs secondary prevention of sudden death in patients with idiopathic dilated cardiomyopathy.
Zecchin M; Di Lenarda A; Proclemer A; Faganello G; Facchin D; Petz E; Sinagra G
Europace; 2004 Sep; 6(5):400-6. PubMed ID: 15294264
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis.
Kron J; Sauer W; Schuller J; Bogun F; Crawford T; Sarsam S; Rosenfeld L; Mitiku TY; Cooper JM; Mehta D; Greenspon AJ; Ortman M; Delurgio DB; Valadri R; Narasimhan C; Swapna N; Singh JP; Danik S; Markowitz SM; Almquist AK; Krahn AD; Wolfe LG; Feinstein S; Ellenbogen KA
Europace; 2013 Mar; 15(3):347-54. PubMed ID: 23002195
[TBL] [Abstract][Full Text] [Related]
17. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
Maron BJ; Spirito P; Ackerman MJ; Casey SA; Semsarian C; Estes NA; Shannon KM; Ashley EA; Day SM; Pacileo G; Formisano F; Devoto E; Anastasakis A; Bos JM; Woo A; Autore C; Pass RH; Boriani G; Garberich RF; Almquist AK; Russell MW; Boni L; Berger S; Maron MS; Link MS
J Am Coll Cardiol; 2013 Apr; 61(14):1527-35. PubMed ID: 23500286
[TBL] [Abstract][Full Text] [Related]
18. Induction of ventricular fibrillation rather than ventricular tachycardia predicts tachyarrhythmia recurrences in patients with idiopathic dilated cardiomyopathy and implantable cardioverter defibrillator for secondary prophylaxis.
Rolf S; Haverkamp W; Borggrefe M; Breithardt G; Bocker D
Europace; 2009 Mar; 11(3):289-96. PubMed ID: 19095687
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic catheter ablation for induced monomorphic ventricular tachycardia in patients with implantable cardioverter defibrillators as primary prevention.
Hayashi T; Fukamizu S; Hojo R; Komiyama K; Tanabe Y; Tejima T; Soejima K; Nishizaki M; Hiraoka M; Ako J; Momomura S; Sakurada H
Europace; 2013 Oct; 15(10):1507-15. PubMed ID: 23603305
[TBL] [Abstract][Full Text] [Related]
20. Appropriate therapies predict long-term mortality in primary and secondary prevention of sudden cardiac death.
Stabile G; D'Agostino C; Gallo P; Marrazzo N; Iuliano A; De Simone A; Turco P; Palella M; Donnici G; Ciardiello C; Napolitano G; Solimene F
J Cardiovasc Med (Hagerstown); 2013 Feb; 14(2):110-3. PubMed ID: 22367567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
